https://www.selleckchem.com/pr....oducts/nvp-tae226.ht
d 14 February 2019. In the phase III ALCYONE trial, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) significantly improved overall response rate and progression-free status compared with VMP alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). Here, we present patient-reported outcomes (PROs) from ALCYONE. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item (EORTC QLQ-C3 and EuroQol 5-dimensional descriptive system (EQ-5D-5L) questionnai
Giống
Bình luận
Đăng lại
